<DOC>
	<DOCNO>NCT00393744</DOCNO>
	<brief_summary>The primary objective study demonstrate non-inferiority , assessment visit ( V3 ( D10/D14 ) ) , term bacteriological efficacy pristinamycin ( PRI ) administer 4 day versus amoxicillin ( AMX ) administer 6 day treatment tonsillitis cause GAS , subject age 6 25 per protocol ( PP ) group .</brief_summary>
	<brief_title>Efficacy Study Pristinamycin Versus Amoxicillin Treat Tonsillitis Induced Streptococcus Children</brief_title>
	<detailed_description />
	<mesh_term>Tonsillitis</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Pristinamycin</mesh_term>
	<criteria>subject sex age 6 25 year , weight : ≥ 20kg suspect GASinduced tonsillitis ( erythema and/or exudate pharynx and/or tonsil oropharyngeal pain and/or odynophagia , fever ³ 38°C , appreciable satellite adenopathy ) confirmation positive RDT provision throat swabs culture ability swallow tablet Related study disease : suspected viral infection ( concomitant dysphonia , cough , conjunctivitis , rhinitis ) adenophlegmon , peritonsillar abscess . Related study treatment : know suspect allergy betalactamines ( penicillin , cephalosporin ) suspect infectious mononucleosis ( increase risk skin disorder ) phenylketonuria ( due presence aspartame ) congenital galactosaemia , glucose/galactose malabsorption syndrome , lactase deficiency ( due presence lactose , powder suspension form ) allergy pristinamycin and/or virginiamycin history pustular rash pristinamycin hypersensitivity gluten intolerant ( due presence wheat starch ) ongoing treatment cyclosporine , methotrexate , colchicine , allopurinol , tacrolimus oral anticoagulant . Related previous treatment : subject receive antibiotic therapy month prior inclusion , except azithromycin , exclusion period 3 month . subject shortterm corticosteroid . Subjects longterm corticosteroid initiate start study take controlled dosage may include . Related subject : breastfeed woman woman either pregnant attempt conceive subject likely , course study receive treatment prohibit protocol treatment investigational drug 4 week prior inclusion study immunodepression , clinically significant endocrine disease , cardiovascular disease , neurological disease , mark disease result complication performance study interpretation study data know hepatic impairment know renal impairment ( creatinine clearance &lt; 30 ml/minute ) cancer , blood dyscrasia previous history drug alcohol abuse . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>